STING1 and neoplasm: Studies using STING agonists alone or in combination with other drugs have shown promising results, such as the use of STING agonist DMXAA in combination with chemotherapy drug SN38, which demonstrated strong anti-tumor effects in melanoma and colon cancer (5–7).